Active, not recruitingPHASE2, PHASE3NCT05203679
Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug
Studying Hemophilia B
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Xinzhi BioMed Co., Ltd.
- Principal Investigator
- Lei Zhang, MDInstitute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
- Intervention
- Single dose intravenous injection of BBM-H901(genetic)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2021 – 2028
Study locations (9)
- Anhui Provincial Hospital, Hefei, Anhui, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China
- The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China
- North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
- Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin Municipality, China
- The second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05203679 on ClinicalTrials.govOther trials for Hemophilia B
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07285460A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BSanofi
- RECRUITINGPHASE3NCT07080905Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BCSL Behring
- RECRUITINGPHASE1, PHASE2NCT06611436BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia BBe Biopharma
- ACTIVE NOT RECRUITINGPHASE3NCT06569108Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE3NCT06003387Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)CSL Behring
- RECRUITINGNCT06008938An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BCSL Behring
- RECRUITINGNANCT05630651The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05709288Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldInstitute of Hematology & Blood Diseases Hospital, China